Pembrolizumab for advanced basal cell carcinoma: An investigator-initiated, proof-of-concept study

J Am Acad Dermatol. 2019 Feb;80(2):564-566. doi: 10.1016/j.jaad.2018.08.017. Epub 2018 Aug 24.

¹ Department of Dermatology, Stanford University School of Medicine, Stanford, California. Electronic address: alschang@stanford.edu.
² Department of Dermatology, Stanford University School of Medicine, Stanford, California.
³ Stanford Cancer Institute, Cancer Clinical Trials Office, Stanford, California.
⁴ Stanford Dermatopathology Service, Department of Pathology, Stanford University School of Medicine and Stanford Cancer Institute, Stanford, California.
⁵ Department of Epithelial Biology, Stanford University School of Medicine and Stanford Cancer Institute, Stanford, California.
⁶ Department of Medicine/Medical Oncology, Stanford University School of Medicine and Stanford Cancer Institute, Stanford, California.

No abstract available

Publication types